J&J Unveils New AFib Treatments and Data at Major Symposium

Company showcases innovations in pulsed field ablation and 4D intracardiac imaging for atrial fibrillation care.

Feb. 3, 2026 at 7:47am

Got story updates? Submit your updates here. ›

Johnson & Johnson is presenting a series of innovations in atrial fibrillation (AFib) treatment, including updates to its Pulsed Field Ablation (PFA) and Ultrasound portfolios, at the 31st Annual AF Symposium in Boston. Key developments include the VARIPULSE Plus Platform, which integrates ablation and mapping, and the NUVISION NAV Ultrasound Catheter, the world's first 4D intracardiac imaging catheter fully integrated with a 3D electroanatomical mapping system.

Why it matters

As a global leader in heart rhythm disorder treatments, Johnson & Johnson's continued advancements in AFib technologies aim to improve procedural precision, efficiency, and patient outcomes. These innovations come as the company sponsors a new registry to capture real-world data on pulsed field ablation procedures, underscoring its commitment to evidence-based innovation in arrhythmia care.

The details

Johnson & Johnson is showcasing the VARIPULSE Plus Platform, an update to its PFA technology that incorporates automated irrigation flow to enhance procedural confidence. The company is also announcing the full commercial release of the NUVISION NAV Ultrasound Catheter, the world's first 4D intracardiac imaging catheter integrated with a 3D electroanatomical mapping system, intended to improve anatomical visualization and guide complex electrophysiology procedures.

  • The 31st Annual AF Symposium is taking place this week in Boston.
  • In March 2024, Biosense Webster, a Johnson & Johnson subsidiary, filed for FDA approval of the Varipulse pulsed field ablation platform.
  • In September 2025, Johnson & Johnson unveiled results from the VARIPURE substudy of SECURE, demonstrating a strong safety profile and high acute effectiveness of the VARIPULSE Platform.
  • In December 2025, Johnson & Johnson announced its sponsorship of a new data collection platform developed by the Heart Rhythm Society to capture real-world data on pulsed field ablation procedures.

The players

Johnson & Johnson

A global healthcare company and a leader in heart rhythm disorder treatments, including mapping and navigation technologies, miniaturized devices, and precise ablation techniques.

Michael Bodner

Company Group Chair, Electrophysiology & Neurovascular, MedTech, Johnson & Johnson.

Got photos? Submit your photos here. ›

What they’re saying

“Evidence-based innovation is the foundation of how we advance arrhythmia care. The data and technology updates we are sharing at AF Symposium demonstrate how we are continuously strengthening our electrophysiology portfolio. These technology advancements and upcoming iterations are built on our scientific foundation and will continue raising the bar for AFib ablation.”

— Michael Bodner, Company Group Chair, Electrophysiology & Neurovascular, MedTech, Johnson & Johnson

What’s next

Johnson & Johnson will host educational programs, in-booth presentations, and training opportunities at the AF Symposium, allowing attendees to experience the VARIPULSE Plus Platform's automated irrigation-flow control and the NUVISION NAV Ultrasound Catheter in simulated procedures.

The takeaway

Johnson & Johnson's continued investments in innovative AFib technologies, coupled with its sponsorship of a new data registry, underscore the company's commitment to advancing evidence-based solutions that can improve procedural precision, efficiency, and patient outcomes in the treatment of heart rhythm disorders.